Serum Uric Acid Levels and Uric Acid/Creatinine Ratios in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients: Are These Parameters Efficient Predictors of Patients at Risk for Exacerbation and/or Severity of Disease?
BACKGROUND Serum uric acid (sUA) levels were previously found to be correlated with hypoxic states. We aimed to determine the levels of sUA and sUA/creatinine ratios in stable COPD patients and to evaluate whether sUA level and sUA/creatinine ratio can be used as predictors of exacerbation risk and disease severity. MATERIAL AND METHODS This cross-sectional study included stable COPD patients and healthy controls. The sUA levels and sUA/creatinine ratios in each group were evaluated and their correlations with the study parameters were investigated. ROC analyses for exacerbation risk and disease severity were reported. RESULTS The study included 110 stable COPD patients and 52 healthy controls. The mean sUA levels and sUA/creatinine ratios were significantly higher in patients with COPD compared to healthy controls. The most common comorbidities in COPD patients were hypertension, diabetes, and coronary artery disease. While sUA levels were significantly higher in patients with hypertension (p=0.002) and malignancy (p=0.033), sUA/creatinine ratios was higher in patients with malignancy (p=0.004). The ROC analyses indicated that sUA/creatinine ratios can be more useful than sUA levels in predicting exacerbation risk (AUC, 0.586 vs. 0.426) and disease severity (AUC, 0.560 vs. 0.475) especially at higher cut-off values, but with low specificity. CONCLUSIONS Our study suggested that sUA levels and sUA/creatinine ratios increased in patients with stable COPD, especially among patients with certain comorbidities compared to healthy controls. At higher cut-off values, sUA levels and especially sUA/creatinine ratios, might be useful in predicting COPD exacerbation risk and disease severity. Also, their association with comorbidities, especially with malignancy and hypertension, may benefit from further investigation.
Department of Pulmonary Diseases, Sureyyapasa Chest Diseases and Thoracic Surgery Education and Research Hospital, Istanbul, Turkey.
Nagihan
N
Durmus Kocak
Department of Nephrology, Medeniyet University Goztepe Education and Research Hospital, Istanbul, Turkey.
Gulsah
G
Sasak
Department of Pulmonary Diseases, Sureyyapasa Chest Diseases and Thoracic Surgery Education and Research Hospital, Istanbul, Turkey.
Ulku
U
Aka Akturk
Department of Pulmonary Diseases, Ataturk University, School of Medicine, Erzurum, Turkey.
Metin
M
Akgun
Department of Pulmonary Diseases, Sureyyapasa Chest Diseases and Thoracic Surgery Education and Research Hospital, Istanbul, Turkey.
Sibel
S
Boga
Department of Pulmonary Diseases, Sureyyapasa Chest Diseases and Thoracic Surgery Education and Research Hospital, Kocaeli, Turkey.
Aysun
A
Sengul
Department of Pulmonary Diseases, Sureyyapasa Chest Diseases and Thoracic Surgery Education and Research Hospital, Istanbul, Turkey.
Sinem
S
Gungor
Department of Pulmonary Diseases, Sureyyapasa Chest Diseases and Thoracic Surgery Education and Research Hospital, Istanbul, Turkey.
Sibel
S
Arinc
D000368:Aged; D016022:Case-Control Studies; D003404:Creatinine / Q000097:blood*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D029424:Pulmonary Disease, Chronic Obstructive / Q000097:blood*; D012372:ROC Curve; D012307:Risk Factors; D012720:Severity of Illness Index; D014527:Uric Acid / Q000097:blood*
D014527:Uric Acid; D003404:Creatinine